Sarcopenia, muscle weakness Musculoskeletal Diseases Other specified disorders of muscle
Conditions
Interventions
Current interventions as of 08/12/2023:
The trial is a before and after-comparison trial. All participants will receive the study medication (acipimox) and aspirin (some participants may be taking asp
Sponsors
Newcastle upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 08/12/2023: 1. Age 65 years and over 2. Low maximum handgrip strength (15 seconds 3. Walk speed <=0.8 m/s on 4-metre walk test Previous participant inclusion criteria: 1. Age 65 years or over 2. Low maximum handgrip strength (<16kg for women, <27kg for men) 3. Walk speed <=0.8 m/s on 4 metre walk test
Exclusion criteria
Exclusion criteria: 1. General: 1.1. Allergy to acipimox or other niacin-related products 1.2. Allergy or intolerance of aspirin 1.3. Unable to give written informed consent 1.4. Currently enrolled in another intervention study (observational studies are permitted) 1.5. Currently participating in supervised exercise classes or physiotherapy 1.6. Any progressive neurological or malignant condition with life expectancy 3x upper limit of normal 4.2. Symptomatic (NYHA class II-IV) chronic heart failure (diagnosed according to European Society of Cardiology guidelines) 4.3. Severe Chronic obstructive pulmonary disease (GOLD stage IV) 4.4. Known myositis or other established myopathy (muscle disease) 4.5. Self-reported weight loss of >10% in last 6 months (to exclude significant cachexia) 4.6. Known uncontrolled thyrotoxicosis (overactive thyroid disease) 4.7. 7.5mg/day or greater prednisolone use (or equivalent) (steroid that can cause muscle weakness)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skeletal muscle NAD concentration measured using a Jamar dynamometer. at baseline and follow up (2 - 3 weeks). Three readings per hand will be taken, with the maximum value used for analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline and follow up (2 - 3 weeks): 1. Mitochondrial Respiratory chain activity via immunohistochemistry and immunofluorescence 2. ATP/ADP concentrations and ratio measured using bioluminescence assays 3. Mitochondrial DNA copy number via quantitative PCR (as a measure of mitochondrial numbers) 4. Erythrocyte NAD concentration measured using bioluminescence assays 5. Peripheral blood white cell NAD concentration measured using bioluminescence assays 6. Phosphocreatine recovery rate measured via 31P magnetic resonance spectroscopy of the calf 7. NAD(P)H levels in skeletal muscle via 31P magnetic resonance spectroscopy of the calf 8. Short Physical Performance Battery 9. Maximal handgrip strength measured using Jamar dynamometer 10. Physical activity, gait speed, variability and postural control measured using triaxial accelerometry | — |
Countries
England, United Kingdom
Outcome results
None listed